SCHEMBL2644357

SCHEMBL2644357

CCCN[C@@H](C)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2644360 1.00
SCHEMBL4618860 1.00
Hydrochloric Acid SCHEMBL19876854 0.98 LMNA (0.45)
Hydrochloric Acid SCHEMBL19876853 0.98 LMNA (0.45)
SCHEMBL14037307 0.87 TSHR (0.40)
SCHEMBL20677353 0.87 TSHR (0.40)
SCHEMBL574347 0.86 FAAH (0.46)
SCHEMBL6054606 0.86 FAAH (0.46)
SCHEMBL290509 0.86 FAAH (0.46)
SCHEMBL10952947 0.85 MME (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4466069-A1 GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF Novo Nordisk A/S (DK) 2024-11-27 EP claimed
CN-118632867-A GLP-1/GIP receptor co-agonist prodrugs and uses thereof 诺和诺德股份有限公司 2024-09-10 CN claimed
US-20240083965-A1 PRODRUGS AND USES THEREOF NOVO NORDISK AS (DK) 2024-03-14 US claimed
WO-2023139187-A1 GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF NOVO NORDISK A/S (DK) 2023-07-27 WO claimed
US-20230227521-A1 PRODRUGS AND USES THEREOF NOVO NORDISK A/S (DK) 2023-07-20 US claimed
WO-2009051555-A2 MODIFIED MHC CLASS I BINDING PEPTIDES AKADEMISCH ZIEKENHUIS LEIDEN (NL) 2009-04-23 WO claimed
EP-0950046-B1 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS NAEJA PHARMACEUTICAL INC (CA) 2002-04-10 EP claimed
US-6232305-B1 ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS NAEJA PHARMACEUTICAL INC. (CA) 2001-05-15 US claimed
EP-0961779-A1 SUBSTITUTED AMINO BICYCLIC-$g(b)-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS SYNPHAR LABORATORIES INC. (CA) 1999-12-08 EP claimed
WO-1998032766-A1 SUBSTITUTED AMINO BICYCLIC-β-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS SYNPHAR LABORATORIES INC. (US) 1998-07-30 WO claimed
US-4405578-A CARBON DIOXIDE, ABSORPTION EXXON RESEARCH AND ENGINEERING CO. (US) 1983-09-20 US claimed
US-20260091092-A1 Methods Of Treating Plantar Fibromatosis ENDO BIOLOGICS LTD (IE) 2026-04-02 US disclosed
US-20260091093-A1 Methods Of Treating Plantar Fibromatosis ENDO BIOLOGICS LIMITED (IE) 2026-04-02 US disclosed
US-20260034199-A1 Methods Of Treating Plantar Fibromatosis ENDO BIOLOGICS LIMITED (IE) 2026-02-05 US disclosed
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-29 US disclosed
WO-1998032766-A1 SUBSTITUTED AMINO BICYCLIC-β-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS SYNPHAR LABORATORIES INC. (US) 1998-07-30 WO disclosed
EP-0384522-B1 Antiviral tetrahydroimidazo[1,4]benzodiazepin-2-thiones JANSSEN PHARMACEUTICA N.V. (BE) 1993-01-13 EP disclosed
WO-1991004246-A1 METHOD FOR PREPARING AMINO ACID DERIVATIVES AND THERAPEUTICAL APPLICATIONS OF SAME SOCIETE CIVILE BIOPROJET (FR) 1991-04-04 WO disclosed
EP-0384522-A1 Antiviral tetrahydroimidazo[1,4]benzodiazepin-2-thiones JANSSEN PHARMACEUTICA N.V. (BE) 1990-08-29 EP disclosed
EP-0038758-A1 Amino-acids derivatives and their therapeutic use SOCIETE CIVILE BIOPROJET (FR) 1981-10-28 EP disclosed